title: Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial.
abstract: BACKGROUND
  The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention.
  
  
  METHODS
  Eighty-seven patients were randomized (1:1) to ezetimibe 10mg or placebo in addition to Atorvastatin 80mg. Intravascular ultrasound with iMap was performed at baseline and after 12months in a non-infarct-related artery. Primary endpoint was change in necrotic core (NC). Secondary endpoints were total atheroma volume (TAV) and percentage atheroma volume (PAV).
  
  
  RESULTS
  NC did not change significantly: ezetimibe group 24.9 (11.9, 51.3) mm3to 24.9 (15.3, 54.5) mm3, p=0.76, placebo group 29.4 (16.3, 78.5) mm3to 32.0 (16.0, 88.7) mm3, p=0.30, (p=0.35 between groups). TAV was reduced in the ezetimibe group only: ezetimibe (200.0 (135.6, 311.9) mm3to 189.3 (126.4, 269.1) mm3, p<0.001) compared to placebo group (218.4 (163.5, 307.9) mm3to 212.2 (149.9, 394.8) mm3, p=0.07) (p=0.56 between groups). PAV was reduced in the ezetimibe group only (40.1±8.6% to 39.2±9.0%, p=0.036) compared to placebo group (43.3±9.4% to 42.2±10.7%, p=0.07), p=0.91 between groups.
  
  
  CONCLUSIONS
  Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis.
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark. Electronic address: Mikkel@candmed.dk.
authors.forename: Mikkel
authors.initials: M
authors.lastname: Hougaard
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Henrik Steen
authors.initials: HS
authors.lastname: Hansen
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Lisbeth
authors.initials: L
authors.lastname: Antonsen
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Anders
authors.initials: A
authors.lastname: Junker
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Karsten
authors.initials: K
authors.lastname: Veien
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Lisette Okkels
authors.initials: LO
authors.lastname: Jensen
mesh_terms: D000368:Aged; D000069059:Atorvastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional / Q000379:methods
chemical_list: D000069059:Atorvastatin; D000069438:Ezetimibe
keywords: Atorvastatin; Ezetimibe; IVUS; iMap